And the move will shake up the orthopaedic robotics scene.
Though orthopaedics companies have begun to recover from the second quarter’s horrors, it is clear that the third quarter belongs to the diagnostics specialists.
The new regulatory scheme poses problems – but also opportunities, in the shape of possible alignment with the US.
The effort has implications for international travel and allocating vaccines – but the precise quantitative tests necessary for this do not, as yet, exist.
Welcome to the calm before the Covid-19 storm.
The largest medtech companies have differing business development strategies, but tend to be on the same page on R&D spending.